Rozlytrek FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 6, 2020.
FDA Approved: Yes (First approved August 15, 2019)
Brand name: Rozlytrek
Generic name: entrectinib
Dosage form: Capsules
Company: Genentech, Inc.
Treatment for: Solid Tumors, Non-Small Cell Lung Cancer
Rozlytrek (entrectinib) is a selective tyrosine kinase inhibitor for the treatment of patients with ROS1-positive, metastatic non-small cell lung cancer and neurotrophic tyrosine receptor kinase (NTRK) gene fusion-positive solid tumors.
Development Timeline for Rozlytrek
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.